Skip to content

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Vaxart Announces Positive Results for its Oral Norovirus Vaccine in Phase 1b Clinical Study
Vaxart Announces Positive Results for its Oral Norovirus Vaccine in Phase 1b Clinical Study  
View HTML
Toggle Summary Vaxart Announces Positive Topline Results for its Oral Tablet Vaccine in Phase 2 Influenza Challenge Study View HTML
Toggle Summary Aviragen Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results
ATLANTA , Aug. 31, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the three months and fiscal year ended June 30, 2017. "We have made great strides, working with our Board and financial advisors, in honing in on a select number of
View HTML
Toggle Summary Vaxart to Present at the Jefferies 2017 Healthcare Conference View HTML
Toggle Summary Aviragen Therapeutics Reports Third Quarter Fiscal Year 2017 Financial Results
ATLANTA , May 04, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the three month period ended March 31, 2017, which is the third quarter of the Company's 2017 fiscal year. "We are expeditiously working with our Board and financial
View HTML
Toggle Summary Aviragen Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update
ATLANTA , April 04, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a company focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options, today announced that based on a review of the
View HTML
Toggle Summary Vaxart Announces Positive Phase 1 Study of Oral Norovirus Vaccine View HTML
Toggle Summary Aviragen Therapeutics Announces Top-Line Results from Phase 2b SPIRITUS Trial of Vapendavir
ATLANTA , Feb. 13, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics (NASDAQ:AVIR), a company focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options, today announced top-line data from its Phase 2b SPIRITUS
View HTML
Toggle Summary Aviragen Therapeutics Reports Second Quarter Fiscal Year 2017 Financial Results
Conference Call to be Held Today at 4:30 P.M. ET
View HTML
Toggle Summary Aviragen Therapeutics Announces Top-Line Results from Phase 2a RSV Challenge Study of BTA585
ATLANTA , Feb. 01, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (Nasdaq:AVIR), a company focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options, today announced top-line data from its
View HTML
Toggle Summary Aviragen Therapeutics to Host Conference Call to Report Second Quarter Fiscal Year 2017 Financial Results on February 2, 2017
ATLANTA , Jan. 26, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Thursday, February 2, 2017 at 4:30 p.m.
View HTML
Toggle Summary Aviragen Therapeutics to Present at Stifel 2016 Healthcare Conference
ATLANTA , Nov. 09, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics , Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, today announced that Aviragen's CFO & Executive Vice President Mark Colonnese will present a corporate overview at the Stifel 2016
View HTML
Toggle Summary Aviragen Therapeutics Reports First Quarter Fiscal Year 2017 Financial Results
Conference Call to be Held Today at 4:30 P.M. ET
View HTML
Toggle Summary Aviragen Therapeutics to Host Conference Call to Report First Quarter Fiscal Year 2017 Financial Results on November 3, 2016
ATLANTA , Oct. 27, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Thursday, November 3, 2016 at 4:30 p.m.
View HTML
Toggle Summary Aviragen Therapeutics to Host KOL Meeting on HRV Infections on October 13, 2016 in New York
ATLANTA , Oct. 10, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, announced today that it will host a Key Opinion Leader (KOL) breakfast focused on the growing burden of human rhinovirus (HRV)
View HTML

Log In

Create an account